Role of Topical Tofacitinib in Autoimmune Skin Disorders: An Expert Opinion

September 2024 in “ IP Indian Journal of Clinical and Experimental Dermatology ”

Kiran Godse, Mukesh Girdhar, Soumya Jagadeesan, Ritu Laiker

topical tofacitinib JAK inhibitor alopecia areata vitiligo atopic dermatitis psoriasis autoimmune skin disorders

Studysummary This source discusses the potential of topical JAK inhibitors, like tofacitinib, as effective treatments for autoimmune skin diseases, emphasizing their superior safety profile and minimal adverse effects compared to conventional systemic therapies.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on ijced.org →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs

1 citations , March 2023 in “Clinical, Cosmetic and Investigational Dermatology”

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

research Alopecia Areata in Latin America: Where Are We and Where Are We Going?

December 2022 in “Dermatology and Therapy”

This review discusses the unmet needs and barriers in managing alopecia areata in Latin America, highlighting access constraints and recommending coordinated efforts to improve patient outcomes with promising new treatments.

research An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata

40 citations , August 2022 in “Frontiers in immunology”

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

research Unmet Medical Needs in Chronic, Non-Communicable Inflammatory Skin Diseases

59 citations , June 2022 in “Frontiers in medicine”

This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

research Janus Kinase Inhibitors in Dermatology: General Considerations and Applications in Vitiligo and Alopecia Areata

14 citations , March 2021 in “Actas Dermo-Sifiliográficas”

This review discusses the JAK/STAT signaling pathway's role in immune-mediated skin diseases and examines the efficacy and safety of JAK inhibitors for treating vitiligo and alopecia areata, but reports no new clinical results.

research The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases

70 citations , October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

research A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo

25 citations , April 2019 in “Journal of The American Academy of Dermatology”

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

research Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis

49 citations , May 2018 in “Journal of the American Academy of Dermatology”

This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.

research Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients

48 citations , November 2017 in “Journal of the American Academy of Dermatology”

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.